www.ThePharmaJournal.com

The Pharma Innovation



ISSN (E): 2277-7695 ISSN (P): 2349-8242 NAAS Rating: 5.23 TPI 2022; 11(12): 3418-3420 © 2022 TPI www.thepharmajournal.com

Received: 05-10-2022 Accepted: 07-11-2022

R Ravikumar

Assistant Professor and Head, VUTRC, Perambalur, Tamil Nadu, India

J Selvaraj

Professor and Head, Department of Veterinary Pathology, VCRI, Orathanadu, Tamil Nadu, India

D Ilayabharathi

Assistant Professor, VUTRC, Perambalur, Tamil Nadu, India

Corresponding Author: R Ravikumar Assistant Professor and Head, VUTRC, Perambalur, Tamil Nadu, India

Histopathological and molecular diagnosis of lymphoid leucosis in commercial layer chicken

R Ravikumar, J Selvaraj and D Ilayabharathi

Abstract

Fifteen dead commercial layer birds of 45 weeks age were examined to know the cause of death. The total flock size was 25,000 and birds were raised in cages from day one of age. The total mortality over a period of 15 weeks was 15%. The birds appeared weak and emaciated. At necropsy, liver, spleen, kidney revealed enlargement, mottling, greyish spots/foci with tumour nodules. The tumours were firm in consistency and smooth when cut. Histopathology of liver and kidney were corroborated the gross lesions. Lymphoid leucosis (LL) was confirmed by conducting polymerase chain reaction (PCR).

Keywords: Layer chicken, lymphoid leucosis, PCR, histopathology

Introduction

Avian leucosis viruses (ALVs) are placed in the alpha retrovirus genus of the family Retroviridae and divided into six subgroups based on viral envelope antigens. Subgroups A, B, C, D and J are classified as exogenous viruses and E is endogenous. ALV A-D can induce B cell lymphomas and ALV-J causes myeloid leucosis. ALV is a lymphoproliferative disease of chickens affecting primarily the bursa of Fabricius transforming the B-type lymphocytes (Sathish *et al.*, 2015)^[5]. It produces a monomorphic lymphoid cell infiltrations or tumours in visceral organs.

The ALVs cause erythroid, lymphoid and myeloid leucosis and a variety of other tumours like fibrosarcomas, haemangiomas, nephroblastomas and osteopetrosis. Of the neoplasms included in the leucosis/sarcoma group, lymphoid leucosis (LL) was until recently the commonest form, occurring mainly in the layer type birds. Losses from these disease are of significant economic importance. The present paper describes the histopathological and molecular diagnosis of lymphoid leucosis in commercial layer chicken raised entirely in cages.

Materials and Methods

Fifteen dead commercial layer birds of 45 weeks of age were examined to know the cause of death with a case history of conjunctivitis, off feed, pale comb and 4% loss in production with 15% mortality over a period of 15 weeks. The total flock size was 25000 and all the birds were raised in cages from day one of age. The persistent mortality (0.60% per week) was recorded from 31 to 35 weeks of age and it increased at the age of 36 weeks from 0.60 % to 1.20% per week. The total mortality over a period of 15 weeks (31 to 45 weeks) was 15%.

A detailed necropsy was conducted on dead birds and gross lesions were recorded. The tissue samples from different portions of liver and kidney were collected in 10 % formalin, processed and sections were stained with haemotoxylin and eosin.

Proviral DNA extraction and PCR

Suspected liver and kidney samples were collected in dry ice for PCR confirmation. Proviral DNA extraction from the suspected liver samples was done by DNeasy blood and tissue kit (M/s Qiagen, Germany) and the extraction procedure was followed as per the manufacturer's instruction. Proviral DNA for *pol-env* glycoprotein (*gp* 85) gene of ALV-A (LL) (Amplicon size 1154 bp) was obtained and stored at -20°C until for further analysis. Then, polymerase chain reaction was carried out by using previously reported primer set for LL as shown in Table 1.

Table 1: Primer used	for detection	of ALV- A	(LL)
----------------------	---------------	-----------	------

Virus	Primer	Sequence	Gene and Size	Reference
ALV-A	Forward	F 5'- CCG GAG TGG CTC GCG AGA TGG-3'	Pol-env	Barathidagan (2014)
(LL)	Reverse	R 5 -GCC TATCCG CTG TCACCACTG-3'	<i>gp</i> 85 1154 bp	Barathidasan (2014)

The PCR reactions was carried out in final volume of 25μ l which include volume of 12.5μ l of master mix(2 X),1µl of forward and reverse primer each (10 pmol/µl),7.5µl of deionized water and 3µl of extracted proviral DNA and the above mixture of materials was subjected to PCR in a thermal cycler (Eppendorff) as per the procedure of Gong *et al.* (2013)^[2]. The analysis of PCR product was carried out in 1.5 per cent agarose gel stained with ethidium bromide (0.5µg/ml) and documented under Gel documentation system.

Results and Discussion

Gross pathology

The affected birds appeared weak and emaciated musculature At necropsy, liver revealed diffuse enlargement with greyish



Fig 1: Chicken- LL Liver showing diffuse enlargement with greyish white soft smooth glistening nodules of 1 to 5 mm diameter on the surface




Fig 3: Chicken- LL – Liver - Diffuse severe MLC infiltration in hepatic parenchyma- 400X

white soft smooth glistening nodules of 1 to 5 mm diameter on the surface (Fig.1). Kidney showed enlargement, congestion or mottling with indistinct greyish white foci (1-3 mm) on the surface (Fig.2). The gross changes of liver and kidney observed in this study agreed with the findings of earlier workers (Soujanya *et al.*, 2019 and Ravikumar *et al.*,2019)^[6, 3].

Histopathology

Histopathology study of Lymphoid leucosis (LL) suspected liver showed diffuse severe monomorphic lymphoid cell (MLC) infiltration in hepatic parenchyma (Fig.3). In kidney multifocal severe MLC infiltrating the renal parenchyma were noticed (Fig.4).




Fig 2: Chicken- LL – Kidney showing enlargement, congestion or mottling with indistinct greyish white foci (1-3 mm) on the surface





Fig 4: Chicken - LL - Kidney - Multifocal severe MLC infiltration in renal parenchyma -100X



PCR was conducted at Department of Veterinary Microbiology, Veterinary College and Research Institute, Orathanadu- 614 625 for 5 field samples taken from suspected cases LL and LL was confirmed (Fig 5). Lymphoid leucosis (LL) was diagnosed in commercial layer chicken of 45 weeks age. Clinically birds showed 4% production loss, weak, debilitated with 15 percent mortality over a period of 15 weeks. Histopathologically liver showed diffuse severe monomorphic lymphoid cell (MLC) infiltration in hepatic parenchyma. In kidney multifocal severe MLC infiltrating the renal parenchyma were noticed. The histopathological changes of liver and kidney observed in this study agreed with the findings of earlier workers (Sagarika et al., 2017 and Soujanya et al., 2019)^[4, 6]. The PCR test was highly useful for detection of LL virus (Barathidasan, 2014)^[1].

Acknowledgement

Authors are thankful to the Department of Veterinary Pathology and Department of Veterinary Microbiology, Veterinary College and Research Institute, Orathanadu- 614 625to carry out the part of this work.

References

- 1. Barathidasan R. Molecular pathology and differential diagnosis of viral induced lymphoid tumours in poultry. Ph.D. Thesis submitted to Deemed University, IVRI, Izatnagar, Bareilly, UP, India; c2014.
- Gong Z, Zhang L, Wang J, Chen L, Shan H, Wang Z, Ma H. Isolation and analysis of a very virulent Marek's disease virus strain in china. Virology Journal. 2013;10:55-162.
- Ravikumar Y, Reddy B, Narmatha M, Ramesh G, Mahesh B, Lakshman M. Lymphoid leucosis and Marek's disease in chicken - Gross and histopathological studies. International J of Livestock Res. 2019;9:140-144.
- 4. Sagarika S, Das DD, Panda SK, Das S, Jena B, Sahu RK. Avian leukosis in chickens: A clinico-pathological survey. J Entomol. Zool. Studies. 2017;5:1697-1701.
- 5. Sathish G, Parthiban M, Divya KC, Kumanan K, Vedamanickam S. Detection of avian leukosis viruses in commercial poultry flocks by immunohistochemistry and PCR. Int. J Adv. Res. Biol. Sci. 2015;2:215-224.
- Soujanya S, Lakshman M, Madhuri D. Occurrence of lymphoid leukosis in chicken. The Pharma Innovation J. 2019;8:159-162.